TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06040957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate injection
Description: single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-articular injection of Minimally manipulated adipose tissue
Description: single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
Study: NCT05380830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tied deep-Water Running
Description: 4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tied deep-Water Running
Description: 4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
Study: NCT06369337

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.
Study: NCT05035485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
Study: NCT05896332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active, Open Label iTBS-rTMS
Description: Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
Study: NCT05163379

Intervention type: OTHER
Intervention: MOBILIZATION
Description: EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
Study: NCT05344443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: A dual orexin antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that looks and tastes like Lemborexant tablets
Study: NCT04968249

Intervention type: OTHER
Intervention: Observational
Description: Observational Cohort to understand risk factors for early COPD.

Intervention type: OTHER
Intervention: Observational
Description: Observational Cohort to understand risk factors for early COPD.
Study: NCT06549842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
Study: NCT06028269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone playing a sound
Description: A sound will be played from a portable device (smartphone) during movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone playing a sound
Description: A sound will be played from a portable device (smartphone) during movement
Study: NCT06541535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid resuscitation with isotonic saline only
Description: Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Study: NCT06152224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Leva Pelvic Health System
Description: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
Study: NCT06541535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation with Ringer Lactate
Description: Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Study: NCT06545734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Ischemic Post-conditioning
Description: After thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular therapy
Description: Thrombectomy alone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Thrombectomy alone.
Study: NCT05099328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recast Therapy
Description: Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recast Therapy
Description: Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Syntax Stories
Description: Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Syntax Stories
Description: Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
Study: NCT06152224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Leva Pelvic Health System
Description: The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
Study: NCT04780204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Tenofovir Alafenamide 25 mg oral once daily
Study: NCT05378945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Nasal Spray
Description: Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
Study: NCT04680221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Deposition of liposomal bupivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block
Description: Transversus abdominis plane block performed to deposit anesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Transversus abdominis plane block performed to deposit anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deposition of saline
Description: Deposition of saline
Study: NCT05291208

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined tACS and Cognitive Training Program
Description: The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Traditional Cognitive Training Program
Description: Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
Study: NCT06405373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReCharge
Description: ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TakeCharge
Description: TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
Study: NCT06448871

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound assessment of the right lower extremity muscles
Description: Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry (DXA) scan
Description: skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).
Study: NCT04956393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate 8-Week SOAR Program
Description: This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed 8-Week SOAR Program
Description: This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class.
Study: NCT06193421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride
Description: 75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
Study: NCT06532292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: To facilitate PFM function, electromyography biofeedback and electrical stimulation will be employed using an intravaginal probe, tailored to individual needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFEM
Description: The HIFEM device (i.e. BTL EMSELLA) is FDA approved and its indications are to provide entirely non-invasive electromagnetic stimulation of pelvic floor muscle for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
Study: NCT05178082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video-based Pain Program
Description: Educational videos with 10 modules with information about pain.
Study: NCT06549842

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo Radial Band
Description: Group 1 will receive TR band post cardiac catheterization for radial hemostasis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaosband
Description: Group 2 will receive Vasoband post cardiac catheterization for radial hemostasis.
Study: NCT05302531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole trimethoprim
Description: Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
Study: NCT05430243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: once daily empagliflozin 10mg+/- diuretics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics
Description: diuretics as clinically indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics
Description: diuretics as clinically indicated
Study: NCT05418881

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile Tracking Device (one spot)
Description: Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
Study: NCT05178082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief Program
Description: Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
Study: NCT05418881

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile Tracking Device (one spot)
Description: Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile Tracking Device + Activity Sensor (longitudinal)
Description: Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
Study: NCT04742400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib 60mg
Description: 60 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib 60mg
Description: 60 mg orally
Study: NCT05057429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera Bioelectric Dressing
Description: Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera Bioelectric Dressing
Description: Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Gauze Dressing
Description: Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Gauze Dressing
Description: Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
Study: NCT05162820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100 mg Solarplast
Description: 100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100 mg Solarplast
Description: 100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
Study: NCT05553691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL026
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL026
Description: Intravenous
Study: NCT04683887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tape application
Description: Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
Study: NCT05373433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 750mg
Description: Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSD8432 placebo
Description: Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID